 |
 |
With all the excitement about Phytopharm's Cogane in the last few days, I believe it is important to read between the lines and temper our enthusiasm just a little. It appears that the presentation at the Parkinson's Disease and Movement Disorders conference in Istanbul reported the results of "pre-clinical" studies. This means that they were likely conducted in animals, not humans. Phytopharm's most recently published report (_www.phytopharm.co.uk/files/.co.uk/files/<WBR>news/4200/INTE_ (http://www.phytopharm.co.uk/files/news/4200/INTERIMS2007FINAL1.pdf) ) describes a phase II clinical trial in patients with mild to moderate Alzheimer's. Phase I trials (safety in healthy volunteers) were completed a couple of years earlier. From this information, we can gather that there is some safety data in humans, and data to support an oral dosing regimen (dosage strength, frequency, etc.) in Alzheimer's patients. We don't know what regimen will likely work in PD patients. We don't know when phase II trials in PD patients will begin, which will have to happen before the larger phase III clinical trials to show efficacy can begin. We'll be tracking this drug on the Parkinson's Pipeline Project database (_http://www.pdpipeline.org/_ (http://www.pdpipeline.org/) ), along with many other new therapies. Please keep checking for our latest information. Wilson DeCamp Leesburg, VA (a member of the Parkinson's Pipeline Project) ************************************** See what's free at http://www.aol.com. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn